drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous gene‑modified T cells engineered with a mesothelin‑targeted CAR; co‑expresses a CD40 agonist and a T‑cell costimulatory agonist to enhance activation, proliferation, persistence, and APC licensing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous gene‑modified T cells expressing a mesothelin‑targeted CAR that recognizes MSLN on tumor cells and mediates T‑cell activation and cytotoxicity; co‑expression of a CD40 agonist licenses/activates antigen‑presenting cells, and a T‑cell costimulatory agonist augments T‑cell activation, proliferation, and persistence to enhance antitumor efficacy.
drug_name
Pan‑T booster co‑expressing MSLN CAR‑T cells
nct_id_drug_ref
NCT05693844